Vaccine for RSV and HMPV in adults 60 and older
Part of Infections, Lungs & breathing clinical trials.
This study tests a new vaccine that protects against two common respiratory viruses: RSV and HMPV. It aims to see if the vaccine is safe and works well in older adults, who are at higher risk for serious illness from these viruses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years of age or older.
- You have not received a vaccine for RSV or HMPV in the past.
- You have not been diagnosed with Guillain-Barré syndrome (a rare nerve disorder).
- You do not have a weakened immune system or take medications that suppress the immune system (like long-term steroids).
- You do not have a severe allergic reaction to any ingredients in the vaccine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new vaccine that targets two respiratory viruses, RSV and HMPV, to see if it's safe and effective in adults 60 years and older. It may help prevent serious lung infections caused by these viruses.
This trial tests a new RSV vaccine in two phases. First, it will be given to healthy adults 18 and older to check safety. Then, it will be studied in adults 50 and older, including those with stable health conditions, to see if it helps protect against RSV, a common virus that can cause serious breathing problems in older people.
This trial tests a new mRNA vaccine designed to protect older adults against two common respiratory viruses, RSV and hMPV. It aims to see if the vaccine is safe and creates a good immune response.
This study tests a new vaccine that may protect against two common viruses that cause breathing problems, RSV and hMPV. It is for healthy younger adults (18-49) and older adults (60-80) to see if the vaccine is safe and works well.
This study tests an RSV vaccine to see if it is safe and helps your immune system fight the virus. It's for older adults who are generally healthy, and it may help protect you from severe RSV illness.
This trial tests an experimental vaccine for respiratory syncytial virus (RSV), a common virus that can cause serious lung infections, especially in older adults. The study checks if the vaccine is safe and how the body responds to it.
Hear when a new Respiratory Syncytial Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.